Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 15, 2023 at 04:18 am EDT
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 37,527.62 million compared to KRW 47,136.9 million a year ago. Net loss was KRW 491.81 million compared to net income of KRW 3,247.27 million a year ago.
Basic loss per share from continuing operations was KRW 18 compared to basic earnings per share from continuing operations of KRW 119 a year ago. Basic loss per share was KRW 18 compared to basic earnings per share of KRW 119 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 